Abstract
Promoting osteogenic differentiation and efficacious bone regeneration have the potential to revolutionize the treatment of orthopaedic and musculoskeletal disorders. Mesenchymal Stem Cells (MSCs) are bone marrow progenitor cells that have the capacity to differentiate along osteogenic, chondrogenic, myogenic, and adipogenic lineages. Differentiation along these lineages is a tightly controlled process that is in part regulated by the Bone Morphogenetic Proteins (BMPs). BMPs 2 and 7 have been approved for clinical use because their osteoinductive properties act as an adjunctive treatment to surgeries where bone healing is compromised. BMP-9 is one of the least studied BMPs, and recent in vitro and in vivo studies have identified BMP-9 as a potent inducer of osteogenic differentiation in MSCs. BMP-9 exhibits significant molecular cross-talk with the Wnt/ β-catenin and other signaling pathways, and adenoviral expression of BMP-9 in MSCs increases the expression of osteogenic markers and induces trabecular bone and osteiod matrix formation. Furthermore, BMP-9 has been shown to act synergistically in bone formation with other signaling pathways, including Wnt/ β-catenin, IGF, and retinoid signaling pathways. These results suggest that BMP-9 should be explored as an effective bone regeneration agent, especially in combination with adjuvant therapies, for clinical applications such as large segmental bony defects, non-union fractures, and/or spinal fusions.
Keywords: BMP-9, GDF-2, bone formation, mesenchymal stem cells, fracture healing, bone regeneration, cell-based gene therapy, -catenin, osteogenic, spinal fusions, trabecular bone
Current Gene Therapy
Title: BMP-9 Induced Osteogenic Differentiation of Mesenchymal Stem Cells: Molecular Mechanism and Therapeutic Potential
Volume: 11 Issue: 3
Author(s): Ke Yang, Tong-Chuan He, Rex C. Haydon, Hue H. Luu, Russell R. Reid, Zhong-Liang Deng, Guo-Wei Zuo, Bai-Cheng He, Liang Chen, Yuxi Su, Hong Liu, Ning Hu, Mi Li, Xing Liu, Richard Rames, Gaurav Luther, Enyi Huang, Jian-Li Gao, Stephanie H. Kim, Qiong Shi, Chad Teven, Jinyong Luo, Xiaoji Luo, Yang Bi, Joseph Lamplot, Qing Luo, Quan Kang, Gaohui Zhu and Eric R. Wagner
Affiliation:
Keywords: BMP-9, GDF-2, bone formation, mesenchymal stem cells, fracture healing, bone regeneration, cell-based gene therapy, -catenin, osteogenic, spinal fusions, trabecular bone
Abstract: Promoting osteogenic differentiation and efficacious bone regeneration have the potential to revolutionize the treatment of orthopaedic and musculoskeletal disorders. Mesenchymal Stem Cells (MSCs) are bone marrow progenitor cells that have the capacity to differentiate along osteogenic, chondrogenic, myogenic, and adipogenic lineages. Differentiation along these lineages is a tightly controlled process that is in part regulated by the Bone Morphogenetic Proteins (BMPs). BMPs 2 and 7 have been approved for clinical use because their osteoinductive properties act as an adjunctive treatment to surgeries where bone healing is compromised. BMP-9 is one of the least studied BMPs, and recent in vitro and in vivo studies have identified BMP-9 as a potent inducer of osteogenic differentiation in MSCs. BMP-9 exhibits significant molecular cross-talk with the Wnt/ β-catenin and other signaling pathways, and adenoviral expression of BMP-9 in MSCs increases the expression of osteogenic markers and induces trabecular bone and osteiod matrix formation. Furthermore, BMP-9 has been shown to act synergistically in bone formation with other signaling pathways, including Wnt/ β-catenin, IGF, and retinoid signaling pathways. These results suggest that BMP-9 should be explored as an effective bone regeneration agent, especially in combination with adjuvant therapies, for clinical applications such as large segmental bony defects, non-union fractures, and/or spinal fusions.
Export Options
About this article
Cite this article as:
Yang Ke, He Tong-Chuan, C. Haydon Rex, H. Luu Hue, R. Reid Russell, Deng Zhong-Liang, Zuo Guo-Wei, He Bai-Cheng, Chen Liang, Su Yuxi, Liu Hong, Hu Ning, Li Mi, Liu Xing, Rames Richard, Luther Gaurav, Huang Enyi, Gao Jian-Li, H. Kim Stephanie, Shi Qiong, Teven Chad, Luo Jinyong, Luo Xiaoji, Bi Yang, Lamplot Joseph, Luo Qing, Kang Quan, Zhu Gaohui and R. Wagner Eric, BMP-9 Induced Osteogenic Differentiation of Mesenchymal Stem Cells: Molecular Mechanism and Therapeutic Potential, Current Gene Therapy 2011; 11 (3) . https://dx.doi.org/10.2174/156652311795684777
DOI https://dx.doi.org/10.2174/156652311795684777 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Attacking c-Myc: Targeted and Combined Therapies for Cancer
Current Pharmaceutical Design PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors
Current Drug Targets Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Chelating Agents Used for Plutonium and Uranium Removal in Radiation Emergency Medicine
Current Medicinal Chemistry Inorganic Nanomedicines and their Labeling for Biological Imaging
Current Topics in Medicinal Chemistry Profiling of Autophagy-Associated microRNAs in the Osteosarcoma Cell Line of U2OS
Anti-Cancer Agents in Medicinal Chemistry Estrogen Receptor Neurobiology and its Potential for Translation into Broad Spectrum Therapeutics for CNS Disorders
Current Molecular Pharmacology Investigation of the Metal Bonding Properties of Some ARA-II Compounds Using Spectrofluorimetric Method
Current Drug Therapy Withdrawal Notice: Drug Repurposing for Prospective Anti-Cancer Agents Along with the Clinical Status of the Repurposed Drug
Anti-Cancer Agents in Medicinal Chemistry Histone Deacetylase Inhibitors and Colorectal Cancer: what is new?
Anti-Cancer Agents in Medicinal Chemistry Targeting Apoptosis Pathways in Cancer Therapy
Current Cancer Drug Targets From the Table to the Bedside: Can Food-Derived Sulforaphane be used as a Novel Agent to Treat Leukemia?
Current Cancer Drug Targets Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal Novel Mediators of Vitamin D Signaling in Cancer and Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Control of the Bone Morphogenetic Protein 7 Gene in Developmental and Adult Life
Current Genomics <i>In Vitro</i> Anti-proliferative Properties of Flavonoids Isolated from <i>Artocarpus Heterophyllus</i> on Cancer Cell Lines
The Natural Products Journal Mining Sarcomas by Proteomics Approaches: Ewing Sarcoma on the Spotlight
Recent Patents on Biotechnology Modelling DNA Repair Pathways: Recent Advances and Future Directions
Current Pharmaceutical Design Rhodanine as a Privileged Scaffold in Drug Discovery
Current Medicinal Chemistry Skp2 Inhibitors: Novel Anticancer Strategies
Current Medicinal Chemistry